Drugs / GAP3KO
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03168854 | Jul 2017 → Aug 2019 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02313376 | Dec 2014 → Feb 2015 | malaria | Seattle Children's Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GAP3KO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03168854 ↗ |
| Known as | Pf p52(-)/p36(-)/sap1(-) GAP | “Genetically attenuated parasite created by triple deletion (GAP3KO) by deleting the P52, P36, and SAP1 genes in the NF54 wild-type (WT) strain of Plasmodium falciparum (Pf...” NCT03168854 ↗ |
| Modality | Other / unclassified | “genetically attenuated P. falciparum (GAP3KO)” NCT02313376 ↗ |
| Route | Other | “administered via the bite of 150-200 GAP3KO-infected A. stephensi mosquitoes” NCT02313376 ↗ |